Tango Therapeutics Inc. (NASDAQ: TNGX) appointed Matthew Gall as chief financial officer and added two other executives to support development of its cancer drug vopimetostat.

Gall succeeded Daniella Beckman as CFO effective April 15. He previously served as CFO at Kalaris Therapeutics and iTeos Therapeutics, and held finance and business development roles at Sarepta Therapeutics, Celgene Corporation and Gilead Sciences.

The company also appointed Yen-Ching Chua as chief development operations officer effective June 1. Chua will oversee clinical operations, data management, quality and clinical compliance. She previously led clinical operations at Novocure, Debiopharm International, MorphoSys and Novartis.

Janice Kapty was named senior vice president of corporate strategy and project leadership effective April 15. She will handle portfolio strategy and project management for vopimetostat and other pipeline therapies. Kapty previously led drug development teams at Arvinas, MorphoSys, Constellation Pharmaceuticals, Bristol Myers Squibb and Celgene Corporation.

Vopimetostat is a PRMT5 inhibitor being developed for pancreatic cancer. The Boston-based biotechnology company said it plans to present clinical data this year, including results from a combination trial with Revolution Medicines Inc.'s RAS inhibitors.

"Building on our longstanding scientific leadership and recent clinical progress, Tango has a unique opportunity with vopimetostat to bring a potentially paradigm-shifting treatment to patients with pancreatic and other cancers," said CEO Malte Peters.

Peters thanked departing CFO Beckman for her contributions since the company's founding, including taking Tango public and leading capital raises.